Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Zai Lab Limited Unsponsored ADR (ZLAB : NSDQ)
 
 • Company Description   
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.

Number of Employees: 1,951

 
 • Price / Volume Information   
Yesterday's Closing Price: $36.79 Daily Weekly Monthly
20 Day Moving Average: 597,037 shares
Shares Outstanding: 97.91 (millions)
Market Capitalization: $3,602.07 (millions)
Beta: 1.20
52 Week High: $181.92
52 Week Low: $24.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.84% -1.84%
12 Week -33.41% -26.80%
Year To Date -41.46% -30.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4560 JINKE ROAD BLDG. 1 4F PUDONG
-
SHANGHAI,F4 201210
CHN
ph: 86-21-6163-2588
fax: 86-21-6163-2570
jsteier@burnsmc.com http://www.zailaboratory.com
 
 • General Corporate Information   
Officers
Samantha (Ying) Du - Chief Executive Officer and Chairwoman
Billy Cho - Chief Financial Officer
John Diekman - Director
Nisa Leung - Director
William Lis - Director

Peer Information
Zai Lab Limited Unsponsored ADR (CORR.)
Zai Lab Limited Unsponsored ADR (RSPI)
Zai Lab Limited Unsponsored ADR (CGXP)
Zai Lab Limited Unsponsored ADR (BGEN)
Zai Lab Limited Unsponsored ADR (GTBP)
Zai Lab Limited Unsponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98887Q104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 97.91
Most Recent Split Date: (:1)
Beta: 1.20
Market Capitalization: $3,602.07 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.94 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.75
Price/Cash Flow: -
Price / Sales: 21.07
EPS Growth
vs. Year Ago Period: 67.42%
vs. Previous Quarter: 61.61%
Sales Growth
vs. Year Ago Period: 132.42%
vs. Previous Quarter: 5.78%
ROE
03/31/22 - -37.26
12/31/21 - -49.88
09/30/21 - -
ROA
03/31/22 - -32.90
12/31/21 - -44.28
09/30/21 - -
Current Ratio
03/31/22 - 8.99
12/31/21 - 7.78
09/30/21 - 14.45
Quick Ratio
03/31/22 - 8.86
12/31/21 - 7.68
09/30/21 - 14.34
Operating Margin
03/31/22 - -324.08
12/31/21 - -488.16
09/30/21 - -
Net Margin
03/31/22 - -324.08
12/31/21 - -488.16
09/30/21 - -
Pre-Tax Margin
03/31/22 - -323.22
12/31/21 - -487.43
09/30/21 - -
Book Value
03/31/22 - 13.36
12/31/21 - 14.31
09/30/21 - 16.64
Inventory Turnover
03/31/22 - 3.84
12/31/21 - 3.79
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©